Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo

FASEB Journal

Volumn 26, Issue 8, 2012, Pages 3421-3429

  Bier, Carolin ^a   Knauer, Shirley K ^b   Wünsch, Désirée ^a   Kunst, Lena ^b   Scheiding, Sabine ^c   Kaiser, Markus ^b   Ottmann, Christian ^d   Krämer, Oliver H ^c   Stauber, Roland H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

Chemical biology; Dominant negative; Protease; Protein complex stabilizer; Protein interaction; Threonine aspartase 1

Indexed keywords

ASPARTATE AMMONIA LYASE; ENZYME PRECURSOR; HETERODIMER; MONOMER; MUTANT PROTEIN; PROTEIN C JUN; PROTEIN FOS; TASPASE 1; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; GEL FILTRATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MOTIF;

ALLOSTERIC REGULATION; CELL LINE, TUMOR; ENDOPEPTIDASES; HUMANS; PROTEASE INHIBITORS; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION;

EID: 84864742276     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-202432     Document Type: Article

References (44)

1. Turk, B. (2006) Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799
2. Clausen, T., Kaiser, M., Huber, R., and Ehrmann, M. (2011) HTRA proteases: regulated proteolysis in protein quality control. Nat. Rev. 12, 152-162
3. Drag, M., and Salvesen, G. S. (2011) Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 9, 690-701
4. Bier, C., Knauer, S. K., Klapthor, A., Schweitzer, A., Rekik, A., Kramer, O. H., Marschalek, R., and Stauber, R. H. (2011) Cell-based analysis of structure-function activity of threonine aspartase 1. J. Biol. Chem. 286, 3007-3017
5. Hsieh, J. J., Cheng, E. H., and Korsmeyer, S. J. (2003) Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 115, 293-303 (Pubitemid 37487703)
6. Pless, B., Oehm, C., Knauer, S., Stauber, R. H., Dingermann, T., and Marschalek, R. (2011) The heterodimerization domains of MLL-FYRN and FYRC-are potential target structures in t(4;11) leukemia. Leukemia 25, 663-670
7. Knauer, S. K., Fetz, V., Rabenstein, J., Friedl, S., Hofmann, B., Sabiani, S., Schröder, E., Kunst, L., Proschak, E., Thines, E., Kindler, T., Schneider, G., Marschalek, R., Stauber, R. H., and Bier, C. (2011) Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors. PLoS One 6, e18253
8. Khan, J. A., Dunn, B. M., and Tong, L. (2005) Crystal structure of human Taspase1, a crucial protease regulating the function of MLL. Structure 13, 1443-1452 (Pubitemid 41427584)
9. Chen, D. Y., Liu, H., Takeda, S., Tu, H. C., Sasagawa, S., Van Tine, B. A., Lu, D., Cheng, E. H., and Hsieh, J. J. (2011) Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Res. 70, 5358-5367
10. Zhou, H., Spicuglia, S., Hsieh, J. J., Mitsiou, D. J., Hoiby, T., Veenstra, G. J., Korsmeyer, S. J., and Stunnenberg, H. G. (2006) Uncleaved TFIIA is a substrate for taspase 1 and active in transcription. Mol. Cell. Biol. 26, 2728-2735
11. Bier, C., Knauer, S. K., Docter, D., Schneider, G., Kramer, O. H., and Stauber, R. H. (2011) The importin-alpha/nucleophosmin switch controls Taspase1 protease function. Traffic 12, 703-714
12. Chen, D. Y., Lee, Y., Van Tine, B. A., Searleman, A. C., Westergard, T. D., Liu, H., Tu, H. C., Takeda, S., Dong, Y., Piwnica-Worms, D. R., Oh, K. J., Korsmeyer, S. J., Hermone, A., Gussio, R., Shoemaker, R. H., Cheng, E. H., and Hsieh, J. J. (2011) A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res. 72, 736-746
13. Kar, G., Gursoy, A., and Keskin, O. (2009) Human cancer protein-protein interaction network: a structural perspective. PLoS Comp. Biol. 5, e1000601
14. Arkin, M. R., and Whitty, A. (2009) The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr. Opin. Chem. Biol. 13, 284-290
15. Tanaka, T., and Rabbitts, T. H. (2008) Interfering with protein-protein interactions: potential for cancer therapy. Cell Cycle 7, 1569-1574 (Pubitemid 351881323)
16. Thiel, P., Kaiser, M., and Ottmann, C. (2012) Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? Angew. Chemie 51, 2012-2018
17. Molzan, M., Schumacher, B., Ottmann, C., Baljuls, A., Polzien, L., Weyand, M., Thiel, P., Rose, R., Rose, M., Kuhenne, P., Kaiser, M., Rapp, U. R., Kuhlmann, J., and Ottmann, C. (2012) Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol. Cell. Biol. 30, 4698-4711
18. Knauer, S. K., Moodt, S., Berg, T., Liebel, U., Pepperkok, R., and Stauber, R. H. (2005) Translocation biosensors to study signal-specific nucleo-cytoplasmic transport, protease activity and protein-protein interactions. Traffic 6, 594-606 (Pubitemid 40872360)
19. Knauer, S. K., Carra, G., and Stauber, R. H. (2005) Nuclear export is evolutionarily conserved in CVC paired-like homeobox proteins and influences protein stability, transcriptional activation, and extracellular secretion. Mol. Cell. Biol. 25, 2573-2582 (Pubitemid 40385134)
20. Engels, K., Knauer, S. K., Metzler, D., Simf, C., Struschka, O., Bier, C., Mann, W., Kovacs, A. F., and Stauber, R. H. (2007) Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J. Pathol. 211, 532-540 (Pubitemid 46502429)
21. Knauer, S. K., Bier, C., Habtemichael, N., and Stauber, R. H. (2006) The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep. 7, 1259-1265 (Pubitemid 44835095)
22. Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K. H., Stauber, R. H., Böhmer, F. D., and Heinzel, T. (2009) A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 23, 223-235
23. Stauber, R. H., Knauer, S. K., Habtemichael, N., Bier, C., Unruhe, B., Weisheit, S., Spange, S., Nonnenmacher, F., Fetz, V., Ginter, T., Reichardt, S., Liebmann, C., Schneider, G., and Kramer, O. H. (2012) A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 3, 31-43
24. Labisso, W. L., Wirth, M., Stojanovic, N., Stauber, R. H., Schnieke, A., Schmid, R. M., Kramer, O. H., Saur, D., and Schneider, G. (2012) MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 11, 1593-1602
25. Ginter, T., Bier, C., Knauer, S. K., Sughra, K., Hildebrand, D., Munz, T., Liebe, T., Heller, R., Henke, A., Stauber, R. H., Reichardt, W., Schmid, J. A., Kubatzky, K. F., Heinzel, T., and Kramer, O. H. (2012) Histone deacetylase inhibitors block IFNgamma-induced STAT1 phosphorylation. Cell. Signal. 24, 1453-1460
26. Tenzer, S., Docter, D., Rosfa, S., Wlodarski, A., Kuharev, J., Rekik, A., Knauer, S. K., Bantz, C., Nawroth, T., Bier, C., Sirirattanapan, J., Mann, W., Treuel, L., Zellner, R., Maskos, M., Schild, H., and Stauber, R. H. (2011) Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano. 5, 7155-7167
27. Knauer, S. K., Bier, C., Schlag, P., Fritzmann, J., Dietmaier, W., Rodel, F., Klein-Hitpass, L., Kovacs, A. F., Doring, C., Hansmann, M. L., Hofmann, W. K., Kunkel, M., Brochhausen, C., Engels, K., Lippert, B. M., Mann, W., and Stauber, R. H. (2007) The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 6, 1502-1509
28. Knauer, S. K., and Stauber, R. H. (2005) Development of an autofluorescent translocation biosensor system to investigate protein-protein interactions in living cells. Anal. Chem. 77, 4815-4820 (Pubitemid 41076671)
29. Weber, L. (2010) Patented inhibitors of p53-Mdm2 interaction (2006-2008). Expert Opin. Ther. Patents 20, 179-191
30. Sperandio, O., Reynes, C. H., Camproux, A. C., and Villoutreix, B. O. (2011) Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Disc. Today 15, 220-229
31. Zinzalla, G., and Thurston, D. E. (2009) Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Fut. Med. Chem. 1, 65-93
32. Ordonez, G. R., Puente, X. S., Quesada, V., and Lopez-Otin, C. (2009) Proteolytic systems: constructing degradomes. Methods Mol. Biol. 539, 33-47
33. Simard, J. R., Grutter, C., Pawar, V., Aust, B., Wolf, A., Rabiller, M., Wulfert, S., Robubi, A., Kluter, S., Ottmann, C., and Rauh, D. (2009) High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. J. Am. Chem. Soc. 131, 18478-18488
34. Rose, R., Erdmann, S., Bovens, S., Wolf, A., Rose, M., Hennig, S., Waldmann, H., and Ottmann, C. (2011) Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. Angew. Chemie 49, 4129-4132
35. Ottmann, C., Weyand, M., Sassa, T., Inoue, T., Kato, N., Wittinghofer, A., and Oecking, C. (2009) A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A. J. Mol. Biol. 386, 913-919
36. Yip, C. K., Murata, K., Walz, T., Sabatini, D. M., and Kang, S. A. (2011) Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol. Cell 38, 768-774
37. Shen, X., Meza-Carmen, V., Puxeddu, E., Wang, G., Moss, J., and Vaughan, M. (2008) Interaction of brefeldin A-inhibited guanine nucleotide-exchange protein (BIG) 1 and kinesin motor protein KIF21A. Proc. Natl. Acad. Sci. U. S. A. 105, 18788-18793
38. Schumacher, B., Mondry, J., Thiel, P., Weyand, M., and Ottmann, C. (2011) Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer. FEBS Lett. 584, 1443-1448
39. Hauske, P., Ottmann, C., Meltzer, M., Ehrmann, M., and Kaiser, M. (2008) Allosteric regulation of proteases. Chembiochem 9, 2920-2928
40. Laskowski, R. A., Gerick, F., and Thornton, J. M. (2009) The structural basis of allosteric regulation in proteins. FEBS Lett. 583, 1692-1698
41. Mitternacht, S., and Berezovsky, I. N. (2011) Binding leverage as a molecular basis for allosteric regulation. PLoS Comp. Biol. 7, e1002148
42. Saunders, L. P., Ouellette, A., Bandle, R., Chang, W. C., Zhou, H., Misra, R. N., De La Cruz, E. M., and Braddock, D. T. (2008) Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol. Cancer Ther. 7, 3352-3362
43. Zudaire, E., Aparicio, M., and Cuttitta, F. (2011) Antiangiogenic small molecule and methods of use. WIPO Patent Application WO 2011/014825 A2
44. Bier, C., Knauer, S. K., and Stauber, R. H. (2012) Letter: Targeting Taspase1 for cancer therapy. [E-pub ahead of print] Cancer Res. doi:10.1158/0008-5472.CAN-12-0150